Pigmentation Disorders

- NOTOC**

Pigmentation Disorders

Pigmentation disorders are conditions in which the normal color of the skin, hair, nails, or mucous membranes becomes lighter, darker, uneven, or absent. These changes may result from alterations in melanocyte number, melanin production, melanosome formation or transport, inflammation, genetic mutations, medications, chemical exposures, ultraviolet radiation, hormonal influences, or systemic disease.

The clinical spectrum ranges from common acquired conditions such as melasma and post-inflammatory hyperpigmentation to autoimmune depigmentation in vitiligo, inherited disorders such as albinism, and uncommon syndromes involving pigmentation together with abnormalities of other organs. Pigmentary changes can be medically important, cosmetically noticeable, psychologically burdensome, or signs of an underlying systemic condition.

Hyperpigmentation

Hyperpigmentation occurs when areas of the skin contain increased pigment or appear darker than surrounding skin. The pigment may be located primarily in the epidermis, deposited within the dermis, or involve both layers.

Melasma is one of the most extensively studied acquired hyperpigmentation disorders. It usually produces irregular brown or gray-brown patches on sun-exposed facial skin. Its development appears to involve a combination of ultraviolet radiation, visible light, hormones, genetics, oxidative stress, vascular changes, inflammation, melanocyte activity, and alterations in the dermal environment. Because recurrence is common, photoprotection and long-term maintenance are important parts of management.

Post-inflammatory hyperpigmentation develops after inflammation or injury stimulates excess pigment production. Acne, eczema, trauma, burns, dermatologic procedures, and other inflammatory conditions can leave persistent dark marks after the original problem has resolved. It is particularly prominent in more heavily pigmented skin and can sometimes be worsened by overly aggressive treatment.

Other acquired hyperpigmentation disorders include lichen planus pigmentosus, erythema dyschromicum perstans, Riehl melanosis, solar lentigines, periorbital hyperpigmentation, pigmented purpuric dermatoses, and exogenous ochronosis. These conditions differ in cause and appearance but can overlap clinically, making careful diagnosis important.

Hypopigmentation and Depigmentation

Hypopigmentation refers to reduced pigmentation, while depigmentation generally describes more complete loss of pigment. These changes can arise from autoimmune disease, inflammation, chemical injury, infection, genetic conditions, medications, or developmental abnormalities.

Vitiligo is a major acquired depigmentation disorder characterized by the loss of functional melanocytes. Research increasingly describes vitiligo as an immune-mediated condition involving genetic susceptibility, oxidative stress, inflammatory signaling, and autoimmune destruction of melanocytes. Lesions can occur almost anywhere on the body and may also affect hair pigmentation.

Vitiligo can have substantial psychosocial consequences because visible pigment loss may influence self-image, relationships, social interactions, and quality of life. Treatment therefore involves more than cosmetic repigmentation. Current approaches may include topical medications, phototherapy, systemic treatment, surgical techniques in selected cases, and newer targeted therapies such as Janus kinase inhibitors.

Other causes of reduced pigmentation include post-inflammatory hypopigmentation, chemical leukoderma, idiopathic guttate hypomelanosis, pityriasis alba, progressive macular hypomelanosis, nevus depigmentosus, and tinea versicolor. Chemical leukoderma can occur when certain substances selectively injure melanocytes and may sometimes resemble or trigger vitiligo.

Albinism and Genetic Pigmentation Disorders

Inherited pigmentation disorders demonstrate how genes control melanocyte development, melanin synthesis, melanosome formation, intracellular transport, and pigment distribution.

Oculocutaneous albinism includes several genetic disorders characterized by reduced melanin production affecting the skin, hair, and eyes. Visual impairment is an important component, and reduced cutaneous pigmentation increases vulnerability to ultraviolet damage and skin cancer. Management therefore includes ophthalmologic care, rigorous photoprotection, dermatologic surveillance, genetic evaluation, and psychosocial support.

Some inherited syndromes combine pigmentation abnormalities with other medical findings. Waardenburg syndrome may involve pigmentary differences and hearing loss. Hermansky-Pudlak syndrome can combine albinism with platelet dysfunction and systemic complications. Griscelli syndrome involves abnormal melanosome transport. Piebaldism typically causes stable congenital areas of depigmentation.

Reticulate pigmentary disorders produce mottled or netlike patterns of darker and lighter pigmentation. Examples include Dowling-Degos disease, dyschromatosis universalis hereditaria, dyschromatosis symmetrica hereditaria, reticulate acropigmentation of Kitamura, and Naegeli-Franceschetti-Jadassohn syndrome. Advances in molecular genetics have increasingly allowed these clinically overlapping disorders to be separated according to their underlying mutations.

Syndromic and Systemic Pigmentation

Pigmentary changes sometimes provide clues to disease affecting other parts of the body. Peutz-Jeghers syndrome, for example, combines characteristic mucocutaneous pigmentation with gastrointestinal polyposis and increased cancer risk. Carney complex can include lentigines and other pigmented lesions together with endocrine abnormalities and tumors. Neurofibromatosis type 1 is associated with café-au-lait macules and intertriginous freckling.

Diffuse hyperpigmentation can also occur in endocrine disorders. Addison disease is particularly associated with increased pigmentation of the skin and mucous membranes as a consequence of primary adrenal insufficiency. Pigmentary changes can therefore occasionally be an early diagnostic sign of internal disease.

Acanthosis nigricans produces velvety hyperpigmented plaques, especially in body folds. Although treatment can target the skin itself, identification and management of associated metabolic or systemic abnormalities is often important.

Drug- and Chemical-Induced Pigmentation

Medications can alter pigmentation through several mechanisms, including increased melanin production, deposition of drug metabolites, interactions with iron or other pigments, and effects on melanocyte signaling.

Reported examples include pigmentation associated with minocycline, hydroxychloroquine, chloroquine, and zidovudine. Some drugs may instead reduce pigmentation. Imatinib, for example, has been associated with skin lightening related to interference with signaling pathways involved in melanocyte biology.

Long-term topical exposure can also cause pigmentary complications. Exogenous ochronosis is a difficult-to-treat blue-black discoloration associated especially with prolonged use of hydroquinone. Chemical leukoderma results from exposure to substances capable of damaging melanocytes and illustrates how environmental chemicals can produce pigment loss resembling autoimmune disease.

Diagnosis

Diagnosis of pigmentation disorders begins with the pattern, distribution, color, duration, associated symptoms, family history, medication history, inflammatory skin disease, sun exposure, occupational exposures, and systemic symptoms.

Clinical examination may be supplemented by dermoscopy, Wood's lamp examination, photography, reflectance measurements, imaging techniques, histopathology, genetic testing, or laboratory evaluation when an inherited or systemic disorder is suspected.

Distinguishing epidermal from dermal pigmentation can help guide treatment because pigment located deeper within the skin is generally more difficult to remove. Similarly, distinguishing vitiligo from chemical leukoderma, nevus depigmentosus, post-inflammatory hypopigmentation, infection, and inherited hypopigmentation is important before treatment begins.

Evaluation in people with more heavily pigmented skin requires particular care because inflammatory disorders may produce prominent pigmentary changes, and aggressive procedures can themselves cause hyperpigmentation or hypopigmentation.

Treatment and Photoprotection

Treatment depends on the cause, depth, distribution, severity, and activity of the pigmentary disorder. No single therapy is appropriate for all forms of dyschromia.

For hyperpigmentation, management may include photoprotection, topical lightening agents, retinoids, azelaic acid, chemical peels, tranexamic acid, microneedling, lasers, and light-based devices. Hydroquinone has long been used for hyperpigmentation, although excessive or prolonged exposure can contribute to ochronosis.

Melasma management commonly requires a combination of pigment-reducing treatment and protection from both ultraviolet and visible light. Because relapse is frequent, maintenance therapy and avoidance of triggers are often necessary.

Vitiligo treatment seeks both to control ongoing melanocyte destruction and to promote repigmentation. Topical anti-inflammatory agents, phototherapy, targeted immune therapies, and selected surgical procedures can be used depending on the extent and stability of disease.

Laser and procedural treatments can improve some pigmentation disorders, but outcomes vary considerably. In darker skin types, treatment-induced inflammation may lead to additional dyschromia, making conservative treatment selection and careful technique especially important.

Psychosocial Impact

Pigmentation disorders can affect far more than physical appearance. Vitiligo, melasma, albinism, acne-associated hyperpigmentation, and other visible pigmentary conditions have been associated with effects on self-esteem, social interaction, emotional well-being, and quality of life.

People with albinism may face additional social challenges while also managing visual impairment and increased susceptibility to ultraviolet injury. The medical literature therefore increasingly emphasizes patient-reported outcomes and the importance of evaluating how pigmentary disease affects daily life rather than measuring skin color alone.

Research and Emerging Therapies

Research on pigmentation disorders increasingly combines dermatology, immunology, genetics, photobiology, and molecular medicine. Genetic studies continue to identify pathways controlling melanocytes and melanosomes, while immune research has produced targeted treatments for disorders such as vitiligo.

Newer work also examines more precise methods of measuring pigment, improved dermoscopic and imaging techniques, optimized combinations of topical and procedural treatments, and safer approaches for skin of color.

The expanding understanding of pigmentation biology is gradually shifting treatment from broadly suppressing or removing pigment toward targeting the molecular mechanisms responsible for individual disorders.

Conclusion

Pigmentation disorders encompass a diverse group of conditions ranging from common cosmetic concerns to autoimmune, genetic, endocrine, medication-related, and syndromic diseases. Their appearance reflects complex interactions among melanocytes, melanin synthesis, inflammation, genetics, ultraviolet and visible light, hormones, medications, chemicals, and systemic health.

Accurate diagnosis is essential because disorders that look similar may have very different causes and treatments. Modern management increasingly combines careful clinical evaluation, photoprotection, topical therapy, systemic treatment, procedural techniques, molecularly targeted therapies, and attention to quality of life. Continuing advances in genetics, immunology, and pigment-cell biology are improving both understanding and treatment of these highly varied disorders.

- TOC**

General Reviews, Diagnosis, and Classification (10)

[PMID:41951329 | Miguel A. Aristizabal-Torres et al. | Dermatologic Clinics | 2026]

Pigmentary Disorders in Skin of Color: Histopathologic Overview — Reviews the clinical and microscopic features of major hyperpigmentation and hypopigmentation disorders, emphasizing diagnostic patterns in patients with skin of color.

[PMID:41865981 | M. Mansilla-Polo, C. J. Díaz-Gómez, D. Morgado-Carrasco | Actas Dermo-Sifiliográficas | 2026]

Clinical and Dermoscopic Characteristics of Facial Hyperpigmentation Disorders in Skin of Color — Examines dermoscopic and clinical findings that help distinguish common causes of facial hyperpigmentation in darker skin types.

[PMID:41362125 | Thierry Passeron et al. | Journal of the European Academy of Dermatology and Venereology | 2026]

Global Consensus on the Management of Melanin Hyperpigmentation Disorders — International experts provide consensus recommendations for diagnosing and managing common acquired disorders of excessive melanin pigmentation.

[MedlinePlus:Skin Pigmentation Disorders | National Library of Medicine | MedlinePlus | 2025]

Skin Pigmentation Disorders — Consumer-oriented overview explaining abnormal increases, decreases, and losses of skin pigment and linking pigmentation changes to inherited and acquired conditions.

[DOI:10.1002/der2.146 | Michelle Pagan et al. | Dermatological Reviews | 2023]

Diagnostic Tools for Hyperpigmentation Disorders in Skin of Color: An Updated Review — Reviews Wood's lamp examination, dermoscopy, reflectance methods, imaging, biopsy, and other tools used to evaluate pigmentary disorders.

[PMID:35151757 | Rebecca F. Wang et al. | Journal of the American Academy of Dermatology | 2023]

Disorders of Hyperpigmentation. Part I: Pathogenesis and Clinical Features of Common Pigmentary Disorders — Explains biological mechanisms and clinical features underlying several common disorders characterized by increased pigmentation.

[DermNet:Pigmentation Disorders | DermNet NZ | DermNet | 2023]

Pigmentation Disorders — Clinical reference organizing disorders into hyperpigmentation, hypopigmentation, and depigmentation while illustrating the broad differential diagnosis of abnormal skin color.

[PMCID:PMC9165630 | S. Moolla, Y. Miller-Monthrope | Drugs in Context | 2022]

Dermatology: How to Manage Facial Hyperpigmentation in Skin of Colour — Provides a practical review of the causes, diagnosis, prevention, and treatment of facial hyperpigmentation in people with skin of color.

[PMID:27943085 | Neelam A. Vashi et al. | American Journal of Clinical Dermatology | 2017]

Facial Hyperpigmentation in Skin of Color: Special Considerations and Treatment — Discusses melasma, post-inflammatory hyperpigmentation, and other facial pigment disorders with attention to treatment risks in darker skin.

[PMID:24679999 | Vanessa E. Molinar, Susan C. Taylor, Amit G. Pandya | Dermatologic Clinics | 2014]

What's New in Objective Assessment and Treatment of Facial Hyperpigmentation? — Reviews methods for objectively measuring pigmentation and evaluates established and emerging approaches to treating facial discoloration.

Vitiligo and Acquired Depigmentation (20)

[NCBI Bookshelf:Vitiligo | Divyanshu Srivastava, Nishad C. Sathe, Sadia Masood | StatPearls | 2026]

Vitiligo — Broad clinical review covering epidemiology, proposed causes, clinical presentation, diagnosis, differential diagnosis, treatment options, prognosis, and complications.

[AAD:Vitiligo Diagnosis and Treatment | American Academy of Dermatology | AAD | 2026]

Vitiligo: Diagnosis and Treatment — Explains how dermatologists diagnose vitiligo and outlines treatments including topical medication, phototherapy, systemic treatment, and selected procedures.

[AAD:Vitiligo Signs and Symptoms | American Academy of Dermatology | AAD | 2026]

Vitiligo: Signs and Symptoms — Describes patterns of pigment loss, common body sites, hair color changes, progression, and other clinical features useful for recognizing vitiligo.

[AAD:Vitiligo FAQs | American Academy of Dermatology | AAD | 2026]

Vitiligo: Frequently Asked Questions — Addresses common questions about causes, heredity, progression, contagiousness, sun exposure, treatment, and living with vitiligo.

[AAD:Is Vitiligo a Medical Condition | American Academy of Dermatology | AAD | 2026]

Is Vitiligo a Medical Condition? — Explains why vitiligo is considered an autoimmune medical disorder rather than merely a cosmetic difference and discusses associated health considerations.

[PMID:40008630 | Catalina Retamal, Dan Hartmann, Fernando Valenzuela | Journal of Cutaneous Medicine and Surgery | 2025]

Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon — Surveys current understanding of vitiligo biology alongside topical, phototherapeutic, systemic, surgical, and emerging targeted treatments.

[PMID:40259443 | Jolien Duponselle et al. | Pigment Cell & Melanoma Research | 2025]

Quality Analysis of Measurement Properties of Patient-Reported Outcome Measures for Vitiligo — Evaluates questionnaires and other patient-reported instruments used to measure vitiligo severity, impact, satisfaction, and quality of life.

[PMID:40332460 | Alzahra A. Mohammed et al. | Dermatology and Therapy | 2025]

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis — Pools clinical evidence on oral and topical JAK inhibitors and evaluates their effectiveness and adverse effects.

[PMID:39274437 | Reinhart Speeckaert et al. | Journal of Clinical Medicine | 2024]

Vitiligo: From Pathogenesis to Treatment — Reviews autoimmune mechanisms, melanocyte loss, oxidative stress, genetics, environmental influences, and modern approaches intended to stop disease activity and restore pigmentation.

[PMID:39624766 | Gaurav N. Pathak et al. | Skin Health and Disease | 2024]

Vitiligo: From Mechanisms of Disease to Treatable Pathways — Connects advances in immunology and melanocyte biology with therapeutic pathways that may enable more precise treatment of vitiligo.

[PMID:38417409 | Hyun Jeong Ju, Jung Min Bae | Dermatology | 2024]

Bridging Molecular Mechanism and Clinical Practice in Vitiligo Treatment: An Updated Review — Relates discoveries about immune signaling and melanocyte destruction to clinical decision-making and newer targeted therapies.

[PMID:38552651 | Jennifer Akl et al. | The Lancet Public Health | 2024]

Estimating the Burden of Vitiligo: A Systematic Review and Modelling Study — Uses systematic evidence and modelling to estimate the global prevalence and health burden associated with vitiligo.

[PMID:38139134 | Multiple authors | International Journal of Molecular Sciences | 2023]

Vitiligo: Pathogenesis and New and Emerging Treatments — Explores immune pathways responsible for melanocyte destruction and discusses treatments targeting JAK signaling and other molecular mechanisms.

[PMID:36947026 | Bo Xie et al. | Expert Opinion on Therapeutic Targets | 2023]

Treatment Update for Vitiligo Based on Autoimmune Inhibition and Melanocyte Protection — Reviews therapeutic strategies aimed both at suppressing autoimmune injury and improving melanocyte survival and repigmentation.

[PMID:37027285 | Xinlyu Huang, Xiaolan Ding | Chinese Medical Journal | 2023]

JAK Inhibitors in Vitiligo: A Meta-analysis — Quantitatively evaluates available clinical studies of JAK inhibitors for vitiligo and assesses the extent of treatment-associated repigmentation.

[PMID:35366355 | M. Picardo et al. | Journal of the European Academy of Dermatology and Venereology | 2022]

The Humanistic Burden of Vitiligo: A Systematic Literature Review of Quality-of-Life Outcomes — Synthesizes evidence showing how visible depigmentation can affect emotional health, social interactions, self-image, and daily life.

[PMID:36339066 | Abrahim Abduelmula et al. | JAAD International | 2022]

Management of Vitiligo With Topical Janus Tyrosine Kinase Inhibitor Therapy: An Evidence-Based Review — Reviews clinical evidence supporting topical JAK inhibition as a targeted strategy for repigmenting vitiligo lesions.

[DermNet:Vitiligo | Bushra Alsayaydeh, Amanda Oakley | DermNet | 2022]

Vitiligo — Illustrated clinical reference reviewing classification, autoimmune associations, diagnosis, differential diagnosis, complications, and medical and surgical treatment options.

[PMID:34554406 | Khaled Ezzedine et al. | American Journal of Clinical Dermatology | 2021]

Psychosocial Effects of Vitiligo: A Systematic Literature Review — Reviews evidence concerning stigma, psychological distress, relationships, quality of life, and other psychosocial consequences associated with vitiligo.

[PMCID:PMC8170669 | Multiple authors | Experimental and Therapeutic Medicine | 2021]

Updates and New Medical Treatments for Vitiligo — Reviews conventional treatment and emerging pharmacologic strategies designed to control inflammation and stimulate restoration of pigmentation.

Melasma (15)

[PMID:40996222 | Rashmi Sarkar et al. | Journal of the European Academy of Dermatology and Venereology | 2026]

Delphi Consensus on Melasma Management by International Experts and Pigmentary Disorders Society — Uses expert consensus to address diagnosis, photoprotection, topical agents, systemic treatments, procedures, maintenance, and recurrence.

[PMID:29083744 | Nishad C. Sathe, Marjorie V. Launico | StatPearls | 2026]

Melasma — Clinical overview of epidemiology, risk factors, pathophysiology, diagnostic evaluation, differential diagnosis, management strategies, and prognosis.

[PMID:40022484 | Ali et al. | International Journal of Dermatology | 2025]

Melasma Pathogenesis Explained — Updates understanding of the interacting cellular, hormonal, photobiological, vascular, inflammatory, and genetic processes involved in melasma.

[PMID:39414648 | He Simin et al. | Aesthetic Plastic Surgery | 2025]

Efficacy of Microneedle as an Assisted Therapy for Melasma: Meta-analysis — Evaluates whether microneedling improves results when used to enhance delivery or effects of other melasma treatments.

[DermNet:Melasma | Amanda Oakley, Brent J. Doolan, Monisha Gupta | DermNet | 2025]

Melasma — Illustrated reference discussing facial distribution, risk factors, hormonal influences, ultraviolet and visible light, diagnosis, prevention, and treatment.

[PMID:38843906 | Retaj Calacattawi et al. | Journal of Dermatological Treatment | 2024]

Tranexamic Acid as a Therapeutic Option for Melasma Management: Meta-analysis — Evaluates clinical evidence for oral, topical, injectable, and other tranexamic-acid approaches to reducing melasma pigmentation.

[PMID:38918942 | Nevi Yasnova, Sondang P. Sirait, Githa Rahmayunita | Acta Dermatovenerologica Alpina Pannonica et Adriatica | 2024]

Three Percent Tranexamic Acid Cream Versus Four Percent Hydroquinone Cream for Mixed-Type Melasma in Skin of Color — Compares two topical therapies for reducing pigmentation in patients with mixed-pattern melasma.

[PMID:37737021 | Wenyi Ma et al. | Journal of Cosmetic Dermatology | 2023]

Efficacy and Safety of Laser-Related Therapy for Melasma: Network Meta-analysis — Compares multiple laser-based strategies and ranks their relative effectiveness and safety using network meta-analysis.

[PMID:35904706 | Multiple authors | Dermatology and Therapy | 2022]

Update on Melasma—Part I: Pathogenesis — Reviews current evidence about ultraviolet radiation, visible light, oxidative stress, hormones, genetics, vascular changes, and dermal abnormalities in melasma.

[PMID:35085327 | Yuan Zhu et al. | PLOS ONE | 2022]

Evaluating the Quality of Life Among Melasma Patients Using the MELASQoL Scale: Systematic Review and Meta-analysis — Quantifies the effect of melasma on quality of life using studies employing a disease-specific measurement scale.

[PMID:35122202 | Dihui Lai et al. | Lasers in Medical Science | 2022]

Laser Therapy in the Treatment of Melasma: A Systematic Review and Meta-analysis — Assesses clinical outcomes and adverse effects of laser and light-based approaches for treating melasma.

[PMID:34411403 | Ofir Artzi et al. | Journal of Cosmetic Dermatology | 2021]

The Pathogenesis of Melasma and Implications for Treatment — Reviews evidence that melasma involves melanocytes, ultraviolet and visible light, hormones, vascular factors, inflammation, and changes in the dermal environment.

[PMID:32129968 | Karen Kagha, Sabrina Fabi, Mitchel P. Goldman | Journal of Drugs in Dermatology | 2020]

Melasma's Impact on Quality of Life — Discusses psychological, social, and emotional effects of persistent facial pigmentation and the importance of considering quality of life in management.

[PMID:31735001 | Susruthi Rajanala, Mayra B. C. de Castro Maymone, Neelam A. Vashi | Dermatology Online Journal | 2019]

Melasma Pathogenesis: A Review of the Latest Research, Pathological Findings, and Investigational Therapies — Examines histologic and molecular abnormalities in melasma and how newer biological insights could inform treatment.

[PMID:27224897 | B. Sofen, G. Prado, J. Emer | Skin Therapy Letter | 2016]

Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion — Reviews practical management of two common acquired hyperpigmentation disorders, including topical therapy, procedures, and photoprotection.

Post-Inflammatory Hyperpigmentation and Acne-Associated Pigmentation (14)

[PMID:41847987 | Multiple authors | PubMed-indexed Review | 2026]

A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment — Discusses both darker and lighter pigment changes following inflammation and reviews mechanisms, evaluation, and treatment strategies.

[PMID:42234395 | Jose L. Lopez-Estebaranz, Marta Lopez-Pando, Keila Mitsunaga | American Journal of Clinical Dermatology | 2026]

Practical Therapeutic Strategies for Acne-Induced Hyperpigmentation Across All Skin Types — Reviews prevention and treatment of acne-related dark marks and discusses how treatment can be adapted across the pigmentation spectrum.

[PMID:39953770 | Kristie Mar et al. | Australasian Journal of Dermatology | 2025]

Prevention of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review — Reviews interventions intended to prevent PIH following inflammatory skin disease or dermatologic procedures in darker skin.

[PMID:37843491 | N. Kashetsky, A. Feschuk, M. E. Pratt | Journal of the European Academy of Dermatology and Venereology | 2024]

Post-inflammatory Hyperpigmentation: A Systematic Review of Treatment Outcomes — Synthesizes evidence on topical agents, chemical peels, lasers, light devices, and combination therapies used for PIH.

[PMID:39075672 | Kristie Mar et al. | Journal of Cutaneous Medicine and Surgery | 2024]

Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review — Evaluates evidence for treating PIH specifically in darker skin, where procedures themselves can sometimes provoke additional pigment alteration.

[PMID:36924935 | Multiple authors | PubMed-indexed Consensus Review | 2023]

Treatment Recommendations for Acne-Associated Hyperpigmentation: Delphi Consensus and Literature Review — Develops expert recommendations for simultaneously controlling acne inflammation and preventing or reducing residual pigmentation.

[PMID:35289059 | Noor Anvery, Rachel E. Christensen, McKenzie A. Dirr | Journal of Cosmetic Dermatology | 2022]

Management of Post-inflammatory Hyperpigmentation in Skin of Color: A Short Review — Summarizes preventive measures and topical, procedural, and device-based options for PIH in patients with darker skin tones.

[PMID:34751927 | Valerie D. Callender et al. | American Journal of Clinical Dermatology | 2022]

Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients With Skin of Color — Reviews evidence that retinoids can address both acne lesions and the persistent hyperpigmented marks that frequently follow them.

[PMID:36342741 | Multiple authors | PubMed-indexed Review | 2022]

Racial and Ethnic Variations in Acne: A Practical Algorithm for Treatment and Maintenance — Reviews differences in acne presentation and pigmentary sequelae and proposes treatment strategies for diverse patient populations.

[PMID:28917451 | Narumol Silpa-Archa et al. | Journal of the American Academy of Dermatology | 2017]

Postinflammatory Hyperpigmentation: Comprehensive Overview of Epidemiology, Pathogenesis, Clinical Presentation, and Noninvasive Assessment — Reviews why inflammation produces persistent excess pigment and describes clinical and instrumental approaches for evaluating it.

[DermNet:Postinflammatory Hyperpigmentation | Vanessa Ngan, Amanda Oakley | DermNet | 2015]

Postinflammatory Hyperpigmentation — Clinical overview explaining how epidermal and dermal pigment changes follow inflammation, which conditions commonly cause PIH, and how it can be managed.

[PMID:24190453 | Natalie C. Yin, Amy J. McMichael | American Journal of Clinical Dermatology | 2014]

Acne in Patients With Skin of Color: Practical Management — Explains acne features particularly relevant to darker skin, including the high clinical importance of preventing and treating post-inflammatory hyperpigmentation.

[PMID:20725554 | Erica C. Davis, Valerie D. Callender | Journal of Clinical and Aesthetic Dermatology | 2010]

Postinflammatory Hyperpigmentation: Review of Epidemiology, Clinical Features, and Treatment Options in Skin of Color — Widely cited overview of PIH mechanisms and treatments with particular attention to populations at increased pigmentary risk.

[PMCID:PMC2921758 | Erica C. Davis, Valerie D. Callender | Journal of Clinical and Aesthetic Dermatology | 2010]

Postinflammatory Hyperpigmentation in Skin of Color — Detailed review describing pathogenesis, clinical presentation, sun protection, bleaching agents, retinoids, chemical peels, and laser considerations.

Albinism and Genetic Pigmentation Disorders (15)

[PMID:42044741 | Multiple authors | PubMed-indexed Review | 2026]

European Perspectives on Albinism: Epidemiology, Clinical Features, and Management — Reviews prevalence, ocular and cutaneous manifestations, diagnosis, surveillance, and multidisciplinary management of albinism.

[PMID:42055276 | Ester Moreno-Artero, Jacob Mashiah | La Presse Médicale | 2026]

Oculo-Cutaneous and Syndromic Albinisms: Epidemiology, Clinical Spectrum and Diagnosis — Distinguishes nonsyndromic albinism from disorders in which hypopigmentation occurs with immune, bleeding, neurologic, or other systemic abnormalities.

[PMID:30085560 | Justin R. Federico, Karthik Krishnamurthy | StatPearls | 2026]

Albinism — General clinical review of defective melanin synthesis, ocular abnormalities, photoprotection, dermatologic complications, diagnosis, and management.

[PMID:41127964 | Ken Okamura, Tamio Suzuki | Journal of Dermatology | 2026]

Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations — Links mutations affecting melanocytes, melanosomes, pigment synthesis, and pigment transport to the clinical appearance of inherited pigmentation disorders.

[PMID:41314539 | Fanny Morice-Picard, Modibo Diallo, Benoit Arveiler | La Presse Médicale | 2025]

Recent Advances in Albinism — Reviews new genetic discoveries, classification, diagnosis, complications, and evolving clinical care for inherited disorders of melanin production.

[PMID:40064606 | Panawé Kassang et al. | International Journal of Dermatology | 2025]

Skin Cancers in People With Albinism: An Overview and Review of Literature — Reviews the markedly increased ultraviolet-related skin cancer risk in albinism and emphasizes prevention, screening, and early diagnosis.

[PMID:41516007 | Multiple authors | PubMed-indexed Systematic Review | 2025]

Genetics of Waardenburg Syndrome in Africa: A Systematic Review — Summarizes reported genetic variants and clinical presentations of Waardenburg syndrome in African populations.

[MedlinePlus Genetics:Oculocutaneous Albinism | National Library of Medicine | MedlinePlus Genetics | 2024]

Oculocutaneous Albinism — Explains the genetic basis, characteristic pigmentation and vision abnormalities, inheritance patterns, and recognized molecular types of OCA.

[PMID:37053367 | Mervyn G. Thomas et al. | GeneReviews | 2023]

Oculocutaneous Albinism and Ocular Albinism Overview — Authoritative genetics review covering inheritance, molecular diagnosis, clinical characteristics, surveillance, counseling, and management.

[PMID:35217926 | Multiple authors | PubMed-indexed Review | 2022]

Oculocutaneous Albinism: Epidemiology, Genetics, Skin Manifestation, and Psychosocial Issues — Reviews genetic subtypes, reduced melanin production, skin and eye findings, cancer risk, and psychosocial challenges.

[PMID:36353393 | Jennifer Kromberg et al. | PMC-indexed Review | 2022]

Oculocutaneous Albinism in Southern Africa: Historical Background, Genetic, Clinical and Psychosocial Issues — Examines the high regional burden of albinism together with genetics, clinical complications, stigma, and social consequences.

[PMID:34042219 | Multiple authors | Journal of the European Academy of Dermatology and Venereology | 2021]

Management of Albinism: French Guidelines for Diagnosis and Care — Provides multidisciplinary recommendations for genetic diagnosis, dermatologic surveillance, ophthalmologic care, photoprotection, and patient support.

[PMID:33641308 | Multiple authors | PubMed-indexed Review | 2021]

Primary Immunodeficiency Associated With Hypopigmentation: A Differential Diagnosis Approach — Reviews syndromes in which reduced pigmentation occurs with immune dysfunction, providing clues for recognizing potentially serious systemic disease.

[PMID:31777350 | Multiple authors | Anais Brasileiros de Dermatologia | 2019]

Albinism: Epidemiology, Genetics, Cutaneous Characterization, Psychosocial Factors — Reviews inherited defects in pigmentation alongside skin cancer risk and the social challenges experienced by people with albinism.

[PMID:20127975 | N. Pingault et al. | Human Mutation | 2010]

Review and Update of Mutations Causing Waardenburg Syndrome — Reviews genes and mutations associated with a group of inherited conditions involving pigmentary abnormalities, hearing loss, and characteristic developmental features.

Acquired Dermal Hyperpigmentation, Lichen Planus Pigmentosus, and Ochronosis (10)

[PMID:41700520 | Vignesh Narayan R. et al. | Clinical and Experimental Dermatology | 2026]

Acquired Dermal Macular Hyperpigmentation: A Unified Spectrum of Dermal Pigmentary Dermatoses — Reviews disorders producing slate-gray or brown macules through dermal pigment deposition and discusses their overlapping clinical and pathological features.

[PMID:40965050 | Nawar Tarafdar, Marissa Joseph, Chaocheng Liu | Dermatologic Surgery | 2026]

Laser Therapy for Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans: A Systematic Review — Evaluates the limited clinical evidence for laser treatment of persistent dermal hyperpigmentation caused by LPP and EDP.

[PMID:37767951 | Shikha Shah et al. | International Journal of Dermatology | 2023]

Acquired Dermal Macular Hyperpigmentation: An Overview of the Recent Updates — Summarizes current diagnostic terminology, suspected causes, pathology, dermoscopy, differential diagnosis, and treatment options.

[PMID:35593293 | Multiple authors | Indian Journal of Dermatology, Venereology and Leprology | 2022]

A Delphi Consensus on the Nomenclature and Diagnosis of Lichen Planus Pigmentosus and Related Entities — Uses expert consensus to clarify definitions and diagnostic criteria for overlapping acquired dermal pigmentary conditions.

[PMID:34667751 | Multiple authors | PubMed-indexed Review | 2021]

Acquired Dermal Macular Hyperpigmentation: An Update — Reviews evolving concepts surrounding lichen planus pigmentosus, erythema dyschromicum perstans, Riehl melanosis, and related dermal pigmentation disorders.

[PMID:30176055 | Sujith Prasad W. Kumarasinghe et al. | International Journal of Dermatology | 2019]

Global Consensus Statement on Ashy Dermatosis, Erythema Dyschromicum Perstans, Lichen Planus Pigmentosus, Idiopathic Eruptive Macular Pigmentation, and Riehl's Melanosis — Establishes standardized terminology and diagnostic concepts for several closely related acquired pigmentary disorders.

[PMID:30627620 | Multiple authors | PubMed-indexed Systematic Review | 2019]

Erythema Dyschromicum Perstans: Case Report and Systematic Review of Histologic Presentation and Treatment — Reviews the characteristic gray discoloration, microscopic findings, and limited evidence supporting available treatments.

[PMID:29076159 | Multiple authors | International Journal of Dermatology | 2018]

Lichen Planus Pigmentosus and Its Variants: Review and Update — Reviews the clinical forms, proposed triggers, pathology, differential diagnosis, and therapeutic approaches for this chronic hyperpigmentation disorder.

[PMID:25837718 | Brian J. Simmons et al. | American Journal of Clinical Dermatology | 2015]

Exogenous Ochronosis: A Comprehensive Review of Diagnosis, Epidemiology, Causes, and Treatments — Reviews paradoxical blue-black pigmentation associated particularly with prolonged hydroquinone exposure and discusses diagnosis and difficult treatment.

[PMID:26677264 | Prachi A. Bhattar et al. | Indian Journal of Dermatology | 2015]

Exogenous Ochronosis — Reviews the clinical and histologic characteristics of ochronosis caused by external substances and highlights its association with long-term topical hydroquinone use.

General Pigmentation, Diagnosis, and Skin of Color (10)

[PMID:42153065 | Multiple authors | Cureus / PubMed-indexed Review | 2026]

Post-Inflammatory Hyperpigmentation in Skin of Color: Emerging Therapies and Treatment Algorithms — Reviews newer topical, systemic, and procedural treatments for PIH and proposes practical management approaches for patients with darker skin tones.

[PMID:41589503 | Naoki Oiso | Journal of Dermatology | 2026]

Pigmentary Disorders: Elucidation of Pathogenesis for Recovery of Health and Wellness — Introduces recent advances linking genetic pigmentary disease, vitiligo, chemical leukoderma, and melanocyte biology.

[PMID:39817312 | Brittany N. Lane et al. | International Journal of Dermatology | 2025]

Concurrent Management of Vitiligo and Acquired Disorders of Hyperpigmentation: A Comprehensive Literature Review and Current Practice Gaps — Discusses the unusual clinical challenge of simultaneously treating depigmentation and hyperpigmentation in the same patient.

[PMID:36781686 | Madeleine Sowash, Tina Alster | American Journal of Clinical Dermatology | 2023]

Review of Laser Treatments for Post-Inflammatory Hyperpigmentation in Skin of Color — Examines laser technologies used for PIH while emphasizing the increased risk of treatment-induced dyschromia in highly pigmented skin.

[PMID:37236710 | Multiple authors | Dermatologic Clinics | 2023]

Diagnosing Disorders of Hypopigmentation and Depigmentation in Patients With Skin of Color — Provides a diagnostic approach incorporating history, morphology, Wood's lamp examination, biopsy, and differential diagnosis.

[PMID:33201325 | Multiple authors | Der Hautarzt | 2021]

Treatment of Pigmentation Disorders in Association With Systemic Diseases — Reviews acquired hypermelanosis, hypomelanosis, endocrine pigmentation, drug pigmentation, chemical depigmentation, and non-melanin discoloration.

[PMID:31896404 | Zekayi Kutlubay et al. | Clinics in Dermatology | 2020]

The Color of Skin: Brown Diseases of the Skin, Nails, and Mucosa — Reviews disorders producing brown discoloration, including melasma, drug pigmentation, pigmented purpura, PIH, and systemic causes.

[PMID:23652952 | Multiple authors | Dermatologic Surgery | 2013]

Treating Hyperpigmentation in Darker-Skinned Patients — Surveys dermatologists regarding the diagnosis and treatment of hyperpigmentation affecting the neck, axillae, and periorbital region in patients with darker skin.

[PMID:19555431 | Clio Dessinioti et al. | Experimental Dermatology | 2009]

A Review of Genetic Disorders of Hypopigmentation: Lessons Learned From the Biology of Melanocytes — Uses inherited pigmentation diseases to explain melanocyte development, pigment synthesis, melanosome transport, and melanocyte survival.

[PMID:9125768 | Multiple authors | Journal of Medical Genetics / PubMed-indexed Review | 1997]

Reticulate Hyperpigmentation — Reviews inherited and acquired conditions characterized by reticulated pigmentation and discusses their clinical and genetic distinctions.

Hypopigmentation, Leukoderma, and Vitiligo-Related Disorders (14)

[PMID:41251280 | Yasutaka Kuroda, Lingli Yang, Ichiro Katayama | Journal of Dermatology | 2026]

Pathogenesis of Chemical Leukoderma and Chemical-Induced Vitiligo — Distinguishes reversible localized chemical leukoderma from persistent chemical-triggered vitiligo and discusses melanocyte loss and autoimmunity.

[PMID:41259071 | Emily Lee, Anthony A. Gaspari | Dermatitis | 2026]

Chemical Leukoderma After Allergic Contact Dermatitis and Patch Testing — Reviews chemical depigmentation associated with contact allergens, particularly para-phenylenediamine and related exposures.

[PMID:38814634 | Multiple authors | PubMed-indexed Review | 2024]

Chemical Leukoderma: An Insight of Pathophysiology and Contributing Factors — Reviews occupational and household chemical exposures capable of injuring melanocytes and producing vitiligo-like depigmentation.

[PMID:37700698 | Saad Altalhab | Journal of Dermatological Treatment | 2023]

Modalities of Treatment for Nevus Depigmentosus: Review of the Literature — Reviews surgical, medical, laser, and phototherapeutic attempts to repigment congenital stable hypopigmented patches.

[PMID:32643458 | Pamela N. Madu, Nicole Syder, Nada Elbuluk | Journal of Dermatological Treatment | 2022]

Postinflammatory Hypopigmentation: A Comprehensive Review of Treatments — Reviews pigment loss following inflammation, trauma, and dermatologic treatment, with particular attention to therapeutic approaches.

[PMID:34304679 | Multiple authors | Journal of Cosmetic and Laser Therapy | 2021]

Idiopathic Guttate Hypomelanosis: Presentation and Management — Discusses suspected causes, dermoscopic and histologic findings, differential diagnosis, and newer treatment options for IGH.

[PMID:27206417 | Premjit Juntongjin, Kulwadee Laosakul | American Journal of Clinical Dermatology | 2016]

Idiopathic Guttate Hypomelanosis: A Review of Its Etiology, Pathogenesis, Findings, and Treatments — Reviews the white macules associated with aging and sun exposure and the many medical and procedural treatments attempted for them.

[PMID:27172302 | Multiple authors | Indian Journal of Dermatology | 2016]

Chemical Leukoderma — Explains acquired pigment loss caused by melanocytotoxic chemicals and describes clinical clues that help distinguish it from idiopathic vitiligo.

[PMID:26821466 | Multiple authors | Journal of Dermatological Science / PubMed-indexed Review | 2016]

Leukoderma Caused by Chemicals: Mechanisms Underlying Phenol- and Rhododendrol-Induced Melanocyte Loss — Explains how tyrosinase can convert certain phenolic compounds into products toxic to melanocytes.

[PMID:24320140 | Multiple authors | International Journal of Dermatology | 2014]

Tinea Versicolor in Dark-Skinned Individuals — Explains why Malassezia infection frequently produces conspicuous hypopigmented rather than hyperpigmented lesions in darker skin.

[PMID:21671990 | Multiple authors | Clinical and Experimental Dermatology | 2011]

Postinflammatory Hypopigmentation — Reviews causes, mechanisms, clinical presentation, diagnosis, prognosis, and treatment of reduced pigmentation following skin inflammation.

[PMID:22031655 | Kathryn E. O'Reilly et al. | Dermatology Online Journal | 2011]

Chemical Leukoderma — Presents clinical chemical leukoderma and discusses repeated exposure to substances capable of selectively damaging melanocytes.

[PMID:21063518 | Multiple authors | Indian Journal of Dermatology | 2010]

Chemical Leukoderma: What's New on Etiopathological and Clinical Aspects? — Reviews phenolic and catecholic chemicals implicated in depigmentation and proposes clinical diagnostic criteria.

[PMID:14635084 | Multiple authors | Cancer | 2003]

Imatinib Mesylate Causes Hypopigmentation in the Skin — Describes reversible, possibly dose-related skin lightening associated with inhibition of KIT signaling during imatinib therapy.

Melasma and Facial Hyperpigmentation (15)

[PMID:39444151 | Rashmi Sarkar et al. | International Journal of Dermatology | 2025]

Glutathione as a Skin-Lightening Agent and in Melasma: A Systematic Review — Assesses evidence for oral and topical glutathione while addressing effectiveness and safety concerns.

[PMID:40384140 | Shree Rath et al. | American Journal of Therapeutics | 2025]

Carboxytherapy Versus Platelet-Rich Plasma in the Treatment of Periorbital Hyperpigmentation — Systematically compares two injectable/procedural approaches used for periocular darkening.

[PMID:38018017 | Thais Rodrigues Galache et al. | Photodermatology, Photoimmunology & Photomedicine | 2024]

Photobiomodulation for Melasma Treatment: Integrative Review and State of the Art — Reviews low-level light approaches and their proposed effects on melanogenesis, inflammation, vascular changes, and photoaging.

[PMID:38530985 | Rashmi Sarkar, Ridhima Lakhani | Dermatologic Surgery | 2024]

Chemical Peels for Melasma: A Systematic Review — Reviews prospective studies and randomized trials involving glycolic acid, trichloroacetic acid, and other peeling agents.

[PMID:39574359 | Multiple authors | Photobiomodulation, Photomedicine, and Laser Surgery | 2024]

Intradermal Injection of Tranexamic Acid for the Treatment of Adult Melasma — Meta-analysis comparing intradermal tranexamic acid with topical, oral, microneedling, and other treatment approaches.

[PMID:37584240 | Xiaowei Feng, Hong Su, Jinwei Xie | Journal of Cosmetic Dermatology | 2024]

Microneedling With Topical Tranexamic Acid for Melasma Treatment: Systematic Review and Meta-analysis — Evaluates enhanced tranexamic-acid delivery through microneedling.

[PMID:37457606 | Multiple authors | Cureus | 2023]

Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis — Compares randomized trials of two commonly used topical agents for reducing melasma severity.

[PMCID:PMC10544009 | Multiple authors | Clinical, Cosmetic and Investigational Dermatology | 2023]

Targeted Pigment-Correcting Dark Spot Treatment for Post-Inflammatory Hyperpigmentation and Solar Lentigines — Clinical study evaluating changes in dark-spot intensity, size, contrast, and overall pigmentation.

[PMID:32947652 | Nevine A. Dorgham et al. | Journal of Cosmetic Dermatology | 2021]

Efficacy and Tolerability of Chemical Peeling as a Single Agent for Melasma in Dark-Skinned Patients — Meta-analyzes comparative trials of chemical peeling in patients vulnerable to treatment-associated pigment alteration.

[PMID:33474663 | Multiple authors | Lasers in Medical Science | 2021]

Effects of Laser Therapy on Periorbital Hyperpigmentation: A Systematic Review — Synthesizes clinical trials using different laser wavelengths and platforms to treat dark circles.

[PMID:32472659 | Omkar Sawant, Tabassum Khan | Dermatologic Therapy | 2020]

Management of Periorbital Hyperpigmentation: An Overview of Nature-Based Agents and Alternative Approaches — Reviews botanical and naturally derived ingredients proposed for treating periocular pigmentation.

[PMID:26962392 | Multiple authors | Journal of Clinical and Aesthetic Dermatology | 2016]

Periorbital Hyperpigmentation: A Comprehensive Review — Describes the multifactorial causes of periorbital pigmentation and available topical, peel, laser, and surgical options.

[PMID:24313385 | Multiple authors | Photodermatology, Photoimmunology & Photomedicine | 2014]

Near-Visible Light and UV Photoprotection in the Treatment of Melasma: A Double-Blind Randomized Trial — Demonstrates the importance of protection from visible light as well as ultraviolet radiation in melasma management.

[PMID:24719068 | Wendy E. Roberts | Journal of Drugs in Dermatology | 2014]

Periorbital Hyperpigmentation: Review of Etiology, Medical Evaluation, and Aesthetic Treatment — Reviews pigmentary, vascular, structural, allergic, and systemic contributors to dark circles around the eyes.

[PMID:16631967 | Multiple authors | Journal of the American Academy of Dermatology | 2006]

Treatment of Solar Lentigines — Consensus-oriented review of cryotherapy, lasers, topical retinoids, and other treatments for sun-induced brown macules.

Reticulate and Genetic Pigmentary Disorders (20)

[PMID:40511878 | Multiple authors | Pigment Cell & Melanoma Research | 2025]

SASH1 Mutations and Hereditary Disorders of Pigmentation: Review of Literature — Reviews SASH1-associated dyschromatosis, lentiginosis, melanosome biology, and syndromic manifestations.

[PMID:40093016 | Multiple authors | Frontiers in Medicine | 2025]

Naegeli-Franceschetti-Jadassohn Syndrome: A Systematic Review of Case Studies — Synthesizes cases involving reticulate pigmentation, hypohidrosis, palmoplantar keratoderma, nail abnormalities, and dental findings.

[PMID:37634201 | Multiple authors | Indian Dermatology Online Journal / PubMed-indexed Article | 2023]

Dyschromatosis Universalis Hereditaria — Reviews diffuse mixtures of hyperpigmented and hypopigmented macules and the genes implicated in different DUH subtypes.

[PMID:37353900 | Ding'an Zhou, Pingping Yang, Hongyu Chen | Experimental Dermatology | 2023]

Retyping and Molecular Pathology Diagnosis of Dyschromatosis Universalis Hereditaria — Reviews molecular classification and the clinical overlap among genetically distinct DUH subtypes.

[PMID:33368260 | Carla Stephan, Mazen Kurban, Ossama Abbas | International Journal of Dermatology | 2021]

Dowling-Degos Disease: A Review — Reviews the genetics and clinical spectrum of progressive flexural reticulate hyperpigmentation associated with KRT5 and other genes.

[PMID:33187737 | Asfandyar Mufti et al. | Journal of the American Academy of Dermatology | 2021]

Treatment Outcomes in Confluent and Reticulated Papillomatosis: A Systematic Review — Synthesizes reported responses to antibiotics, retinoids, antifungals, and other treatments.

[PMID:32055533 | Keshavmurthy A. Adya, Arun C. Inamadar, Aparna Palit | Indian Dermatology Online Journal | 2020]

Reticulate Acropigmentation of Kitamura: A Dermoscopic Perspective — Demonstrates dermoscopic characteristics that can help identify this inherited acral hyperpigmentation disorder.

[PMID:30692041 | Michihiro Kono, Masashi Akiyama | Journal of Dermatological Science | 2019]

Dyschromatosis Symmetrica Hereditaria and Reticulate Acropigmentation of Kitamura: An Update — Compares two inherited acral pigmentary diseases associated with ADAR1 and ADAM10.

[PMID:29201043 | H. Alshaikh, F. Alsaif, S. Aldukhi | Dermatology Research and Practice | 2017]

Clinical and Genetic Review of Hereditary Acral Reticulate Pigmentary Disorders — Reviews DSH, DUH, and reticulate acropigmentation of Kitamura with attention to molecular diagnosis.

[PMID:27601929 | Multiple authors | Clinical, Cosmetic and Investigational Dermatology | 2016]

Confluent and Reticulated Papillomatosis: Diagnostic and Treatment Challenges — Discusses differentiation from acanthosis nigricans and tinea versicolor and reviews therapeutic options.

[PMID:24261749 | Multiple authors | Journal of Forensic Sciences | 2014]

Naegeli-Franceschetti-Jadassohn Syndrome in a Saudi Arabian Family — Documents familial pigmentation, hypohidrosis, absent dermatoglyphics, nail dystrophy, and dental abnormalities.

[PMID:22670867 | Multiple authors | Journal of Dermatology | 2012]

Piebaldism — Reviews KIT signaling, melanocyte development, genotype-phenotype relationships, and congenital stable depigmentation.

[PMID:18462451 | Manfred Stuhrmann et al. | Clinical Genetics | 2008]

Dyschromatosis Universalis Hereditaria: Evidence for Autosomal Recessive Inheritance and Identification of a New Locus — Provides genetic evidence for heterogeneity in this inherited pigmentary disorder.

[PMID:17007541 | Noah Scheinfeld | American Journal of Clinical Dermatology | 2006]

Confluent and Reticulated Papillomatosis: A Review of the Literature — Reviews a hyperpigmented reticulated eruption and proposed bacterial, keratinization, hormonal, and fungal mechanisms.

[PMID:12897212 | Multiple authors | Journal of Clinical Investigation / PubMed-indexed Article | 2003]

Griscelli Syndrome Restricted to Hypopigmentation Results From a Melanophilin Defect or MYO5A Exon Deletion — Links abnormal melanosome transport genes to silver-gray hair and characteristic hypopigmentation.

[PMID:12437556 | Khalid Al Hawsawi et al. | Pediatric Dermatology | 2002]

Dyschromatosis Universalis Hereditaria: Report of a Case and Review of the Literature — Describes the characteristic generalized mottled pigmentation pattern and inherited nature of DUH.

[PMID:11138548 | V. Mendiratta et al. | Journal of Dermatology | 2000]

Reticulate Acropigmentation of Kitamura: An Unusual Presentation — Illustrates phenotypic variation that can complicate recognition of this uncommon inherited dyschromia.

[PMID:10071319 | Multiple authors | Journal of the American Academy of Dermatology | 1999]

Dowling-Degos Disease: A Clinical and Histopathologic Study of Six Cases — Describes characteristic flexural pigmentation, comedo-like lesions, pitted scars, and histopathologic abnormalities.

[PMID:2335418 | A. J. Kanwar, S. Kaur, M. Rajagopalan | International Journal of Dermatology | 1990]

Reticulate Acropigmentation of Kitamura — Describes characteristic reticulated pigmented macules affecting the hands and feet.

[PMID:939040 | G. P. Sparrow, P. D. Samman, R. S. Wells | Clinical and Experimental Dermatology | 1976]

Hyperpigmentation and Hypohidrosis: Naegeli-Franceschetti-Jadassohn Syndrome — Classic review describing hereditary reticulate pigmentation together with abnormalities of sweat glands, teeth, palms, soles, and nails.

Syndromic Pigmentation and Lentiginosis (15)

[PMID:38800180 | Multiple authors | Cureus / PubMed-indexed Review | 2024]

Peutz-Jeghers Syndrome: Genetics, Clinical Features, and Management Approaches — Reviews lentiginous pigmentation, intestinal polyposis, molecular genetics, and cancer susceptibility.

[PMID:34650635 | Multiple authors | Experimental and Therapeutic Medicine | 2021]

Peutz-Jeghers Syndrome: Skin Manifestations and Endocrine Anomalies — Discusses characteristic oral and cutaneous pigmented macules together with systemic manifestations.

[PMID:34630667 | Multiple authors | Experimental and Therapeutic Medicine | 2021]

Dermatological and Endocrine Elements in Carney Complex — Reviews lentigines, mucosal pigmentation, blue nevi, myxomas, and endocrine tumors associated with PRKAR1A abnormalities.

[PMID:30283795 | Multiple authors | World Journal of Clinical Cases | 2018]

Mystery Behind Labial and Oral Melanotic Macules: Laugier-Hunziker Syndrome — Reviews oral, lip, acral, and nail pigmentation and important syndromic differential diagnoses.

[PMID:23171219 | Ai-Hua Wei, Wei Li | Pigment Cell & Melanoma Research | 2013]

Hermansky-Pudlak Syndrome: Pigmentary and Non-Pigmentary Defects and Their Pathogenesis — Reviews oculocutaneous albinism, platelet dysfunction, organelle biology, and systemic complications.

[PMID:23668540 | Multiple authors | Journal of Dermatology | 2013]

Hypopigmentation in Hermansky-Pudlak Syndrome — Explains how abnormal formation and trafficking of melanosomes produces reduced pigmentation.

[PMID:23562360 | Multiple authors | Journal of the American Academy of Dermatology / PubMed-indexed Article | 2013]

Laugier-Hunziker Syndrome: Case Report and Review of the Literature — Reviews diagnostic features and differential diagnosis of acquired mucocutaneous pigmentation.

[PMID:23174847 | Multiple authors | International Journal of Oral Science / PubMed-indexed Article | 2012]

Laugier-Hunziker Syndrome: Three Cases and Literature Review — Reviews clinical, histologic, and differential diagnostic features of this benign pigmentation syndrome.

[PMID:20671949 | Lucio Montebugnoli et al. | International Journal of Dentistry | 2010]

Laugier-Hunziker Syndrome: An Uncommon Cause of Oral Pigmentation — Reviews benign oral and nail pigmentation and distinguishes it from diseases with systemic consequences.

[PMID:21199635 | Sophia Rangwala, Christy B. Doherty, Rajani Katta | Dermatology Online Journal | 2010]

Laugier-Hunziker Syndrome: A Case Report and Review of the Literature — Discusses diffuse mucosal pigmentation, melanonychia, diagnosis, and important mimickers.

[PMID:20581245 | Multiple authors | Gut | 2010]

Peutz-Jeghers Syndrome: A Systematic Review and Recommendations for Management — Reviews STK11-associated mucocutaneous pigmentation, gastrointestinal polyps, cancer risks, and surveillance.

[PMID:16420244 | Multiple authors | Traffic / PubMed-indexed Review | 2006]

Hermansky-Pudlak Syndrome: A Disease of Protein Trafficking and Organelle Function — Links defects in intracellular organelles to albinism, bleeding, fibrosis, and immune abnormalities.

[PMID:15649148 | Multiple authors | Pigment Cell Research | 2005]

Pigment Cell-Related Manifestations in Neurofibromatosis Type 1: An Overview — Reviews café-au-lait macules, intertriginous freckling, Lisch nodules, and melanocyte abnormalities in NF1.

[PMID:14576641 | Multiple authors | Archives of Dermatology / PubMed-indexed Article | 2003]

Hyperpigmentation in Chediak-Higashi Syndrome — Describes unusual mixed hyperpigmentation and hypopigmentation in a disorder better known for partial albinism.

[PMID:2347100 | D. Kemmett et al. | Clinical and Experimental Dermatology | 1990]

The Laugier-Hunziker Syndrome: A Clinical Review of Six Cases — Characterizes benign acquired pigmentation involving the lips and oral mucosa.

Café-au-Lait Macules, Acanthosis, and Related Hyperpigmentation (10)

[PMID:41140645 | Multiple authors | PubMed-indexed Systematic Review | 2025]

Efficacy of Topical Treatments for Acanthosis Nigricans: Systematic Review of Randomized Controlled Trials — Compares tretinoin, urea, salicylic acid, glycolic acid, and trichloroacetic acid treatments.

[PMID:39760892 | Multiple authors | PubMed-indexed Review | 2025]

Combinational Treatment Approaches for Acanthosis Nigricans — Reviews use of topical retinoids and combined therapies designed to improve hyperkeratosis and pigmentation.

[PMID:38904687 | David Bitterman et al. | Archives of Dermatological Research | 2024]

Systematic Review of Topical, Laser, and Oral Treatments in Acanthosis Nigricans Clinical Trials — Compares evidence for pharmacologic and device-based treatment of hyperpigmented intertriginous plaques.

[PMID:38253899 | Multiple authors | Lasers in Medical Science / PubMed-indexed Systematic Review | 2024]

Lasers Versus Topical Medications for Acanthosis Nigricans — Compares fractional and long-pulsed lasers with chemical peels and tretinoin.

[PMID:38752605 | Multiple authors | PubMed-indexed Systematic Review | 2024]

Dermatologic Manifestations of Hereditary Hemochromatosis — Reviews iron-related hyperpigmentation along with pruritus, hypertrichosis, porphyria cutanea tarda, and other cutaneous findings.

[PMID:36698243 | Multiple authors | Current Drug Therapy / PubMed-indexed Review | 2023]

Acanthosis Nigricans: An Updated Review — Reviews characteristic velvety hyperpigmented plaques, systemic associations, diagnosis, and treatment.

[PMID:30122971 | Multiple authors | Clinical, Cosmetic and Investigational Dermatology | 2018]

Current Treatment Options for Acanthosis Nigricans — Reviews treatment of the underlying metabolic disorder as well as retinoids, keratolytics, lasers, and other cosmetic therapies.

[PMID:28557715 | Oya Kuseyri et al. | Pediatrics | 2017]

Amyloidosis Cutis Dyschromica, a Rare Cause of Hyperpigmentation — Describes progressive mixed hyperpigmentation and hypopigmentation capable of mimicking endocrine pigmentation.

[PMID:27212418 | Multiple authors | Pediatric Neurology | 2016]

Café-au-Lait Macules and Neurofibromatosis Type 1: A Review of the Literature — Evaluates how often children presenting with isolated multiple café-au-lait macules ultimately receive an NF1 diagnosis.

[PMID:16479403 | Multiple authors | Archives of Dermatological Research | 2006]

Café-au-Lait Spots in Neurofibromatosis Type 1 and Healthy Individuals — Investigates melanocytes, mast cells, stem-cell factor, and possible biological differences between NF1-associated and ordinary café-au-lait macules.

Drug-Induced and Systemic Pigmentation (15)

[PMID:42225327 | Multiple authors | PubMed-indexed Review | 2026]

Hydroxychloroquine-Associated Skin Lesions: Clinical Features and Mechanisms — Reviews pigmentation and other cutaneous adverse effects and discusses mechanisms involving pigment metabolism and lysosomal accumulation.

[PMID:41587556 | Jiawen Dong et al. | Lancet Diabetes & Endocrinology | 2026]

Clinical Features, Investigation, and Management of Addison's Disease — Reviews primary adrenal insufficiency, including the characteristic ACTH-related increase in cutaneous and mucosal pigmentation.

[PMID:38660312 | Ji-Peng Peng et al. | Frontiers in Immunology | 2024]

Hydroxychloroquine-Induced Hyperpigmentation of the Skin and Bull's-Eye Maculopathy — Reviews the clinical characteristics and pathology of hydroxychloroquine-associated pigmentation.

[PMID:35356915 | Multiple authors | Oral Diseases / PubMed-indexed Scoping Review | 2022]

Oral Pigmentation as an Adverse Effect of Chloroquine and Hydroxychloroquine Use — Reviews bluish-gray oral pigmentation, especially involving the hard palate, associated with long-term antimalarial therapy.

[PMID:37907439 | Yusuke Hirota, Takaya Matsushita | Cleveland Clinic Journal of Medicine | 2022]

Hyperpigmentation as a Clue to Addison Disease — Illustrates how diffuse skin and mucosal darkening can provide an early diagnostic clue to adrenal insufficiency.

[PMID:36140482 | Multiple authors | PubMed-indexed Review | 2022]

New Approach to Addison Disease: Oral Manifestations Due to Endocrine Dysfunction — Reviews mucosal pigmentation and other oral changes that may help identify adrenal insufficiency.

[PMID:36348260 | Multiple authors | PubMed-indexed Review | 2022]

Addison's Disease Without Hyperpigmentation in Pediatrics — Shows that absence of the classic pigmentary sign does not exclude primary adrenal insufficiency.

[PMID:32289395 | Multiple authors | Journal of the American Academy of Dermatology | 2020]

Characterizing the Adverse Dermatologic Effects of Hydroxychloroquine: A Systematic Review — Identifies cutaneous hyperpigmentation as an important adverse effect of hydroxychloroquine.

[PMID:28609345 | Multiple authors | American Journal of Dermatopathology | 2017]

Histopathologic Findings of Cutaneous Hyperpigmentation in Addison Disease — Examines epidermal melanin, melanocytes, dermal melanophages, and other microscopic findings in adrenal-associated pigmentation.

[PMID:25100373 | Multiple authors | Endocrine Practice | 2014]

Addison's Disease in Evolution: An Illustrative Case and Literature Review — Demonstrates how increasing skin pigmentation can appear during the evolution of primary adrenal failure.

[PMID:19595269 | Multiple authors | American Journal of Clinical Dermatology / PubMed-indexed Review | 2009]

Minocycline-Induced Skin Pigmentation: An Update — Describes blue-gray, brown, and scar-associated pigmentation patterns produced by prolonged minocycline exposure.

[PMID:12688837 | Multiple authors | American Journal of Clinical Dermatology | 2003]

Cutaneous Manifestations of Endocrine Disorders: A Guide for Dermatologists — Reviews characteristic pigmentation abnormalities associated with adrenal, pituitary, thyroid, and metabolic disorders.

[PMID:7754471 | Multiple authors | PubMed-indexed Review | 1995]

Skin Changes in Endocrine Disorders — Reviews pigment alterations associated with Addison disease, melasma, acanthosis nigricans, vitiligo, and other endocrinopathies.

[PMID:8391520 | Multiple authors | PubMed-indexed Clinical Article | 1993]

Hyperpigmentation in Primary Adrenal Cortex Insufficiency: Addison Disease — Reviews the broad differential diagnosis of generalized pigmentation and its relationship to endocrine disease.

[PMID:1465574 | G. Rahav, S. Maayan | Scandinavian Journal of Infectious Diseases | 1992]

Nail Pigmentation Associated With Zidovudine: A Review and Report of a Case — Reviews dose-related darkening of fingernails and toenails during zidovudine treatment.

Pigmented Purpura and Other Acquired Dyschromias (8)

[PMID:38473891 | Agnieszka Kimak, Agnieszka Żebrowska | International Journal of Molecular Sciences | 2024]

Therapeutic Approach in Pigmented Purpuric Dermatoses: A Scoping Review — Reviews evidence for topical treatments, systemic therapies, phototherapy, and procedural approaches.

[PMID:34486734 | Stephanie Ishack, Shari R. Lipner | International Journal of Dermatology | 2022]

Exogenous Ochronosis Associated With Hydroquinone: A Systematic Review — Reviews risk factors, clinical blue-black pigmentation, histopathology, duration of hydroquinone exposure, and treatment challenges.

[PMID:34070260 | Cristina B. Spigariolo, Serena Giacalone, Gianluca Nazzaro | Journal of Clinical Medicine | 2021]

Pigmented Purpuric Dermatoses: A Complete Narrative Review — Describes Schamberg disease, lichen aureus, Majocchi disease, and other variants characterized by hemosiderin-associated pigmentation.

[PMID:33394507 | Multiple authors | Oral Diseases | 2021]

Oral Pigmented Lesions in Syndromic Individuals: A Systematic Review — Reviews oral pigmentation occurring in syndromes such as Peutz-Jeghers and Laugier-Hunziker and its value as an early diagnostic clue.

[PMID:31983388 | I. Martínez Pallás et al. | Actas Dermo-Sifiliográficas | 2020]

Pigmented Purpuric Dermatosis: A Review of the Literature — Reviews chronic capillaritis disorders that evolve from petechiae and purpura into persistent brown pigmentation.

[PMID:29381224 | Multiple authors | Journal of Cutaneous Pathology | 2018]

Pathological Spectrum and Clinical Correlation of Pigmented Purpuric Dermatosis — Reviews clinical and histologic patterns in more than 100 biopsy-confirmed cases.

[PMID:24284887 | Rachel Kaplan, Shane A. Meehan, Marie Leger | JAMA Dermatology | 2014]

Isotretinoin-Induced Purpura Annularis Telangiectodes of Majocchi and Review of Substance-Induced Pigmented Purpuric Dermatosis — Examines medication-associated forms of chronic purpuric pigmentation.

[PMID:7068304 | H. Rorsman | International Journal of Dermatology | 1982]

Riehl's Melanosis — Discusses facial pigmentation now commonly associated with pigmented contact dermatitis caused by cosmetic and fragrance allergens.

Pigmentation Disorders

Contents